Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.14 by 21.43 percent. This is a 144 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $137.78 million which missed the analyst consensus estimate of $140.68 million by 2.06 percent. This is a 72.54 percent increase over sales of $79.86 million the same period last year.